OraSure Reports $30.9M Revenue, Sees 2027 Break-Even
The Bethlehem-based diagnostics maker posted 14% year-over-year revenue growth in its third quarter of 2026 while still reporting a GAAP operating loss.
Updated on Nov. 10, 2026 in Healthcare

Live Poll
Do you trust large medical companies to put public health ahead of profits?
OraSure Technologies reported total net revenues of $30.9 million for the third quarter of 2026, up 1% from the prior quarter and 14% year-over-year. The company ended the quarter with $148 million in cash and no debt, and reported a GAAP operating loss of $13 million.
Why it matters
The company now expects to reach operational break-even in the second half of 2027, a timeline shaped by shifting growth opportunities. For the Bethlehem community, the results reflect the performance of a local healthcare manufacturer as it balances diagnostics and global public health demand.
OraSure guided to fourth-quarter 2026 revenue of $30 million to $32 million, implying 4.7% full-year growth at the midpoint. The operating loss narrowed by about $3 million from the prior year, though the source does not address the full cost structure behind the change.
The players
OraSure Technologies
A Bethlehem, Pennsylvania-based company that develops and manufactures rapid diagnostic tests, including HIV self-tests and the OraQuick line.
The details
Gross margin improved mainly from operational efficiencies that better absorbed fixed overhead costs. The company is also working to expand access to its OraQuick Ebola 2.0 Rapid Antigen Test, which received Emergency Use Authorization earlier in 2026, and its OraQuick HIV self-test kits are being assembled at a new plant in Uganda.
Timeline
Earlier in 2026: FDA withdrawal of the InteliQuick CT/NG submission and Emergency Use Authorization for the OraQuick Ebola 2.0 test.
September 2026: Quarter-end cash position of $148 million reported.
Second half of 2027: Expected operational break-even.
Healthcare Landscape
The Emergency Use Authorization for the OraQuick Ebola 2.0 test positions OraSure to address an outbreak that has caused about 5,300 deaths in the Democratic Republic of the Congo, the test detects all four Ebola viruses known to infect humans.
The OraQuick HIV self-test and Ebola antigen test expansion could affect how quickly people in Africa access rapid screening. The source does not specify availability timelines or pricing for individual consumers.
The takeaway
OraSure's path to break-even depends on converting its Ebola and HIV testing programs into steady revenue, so readers tracking the company should watch its fourth-quarter results against the $30 million to $32 million guidance range.
Further reading
For more on the regional medical sector, see Healthcare coverage in Bethlehem.
Source note: This article includes information reported by WFMZ.
Live Poll
Do you trust large medical companies to put public health ahead of profits?










